280 related articles for article (PubMed ID: 26314858)
1. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X
Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858
[TBL] [Abstract][Full Text] [Related]
2. ERCC1 and ERCC2 variants predict survival in gastric cancer patients.
Li Y; Liu Z; Liu H; Wang LE; Tan D; Ajani JA; Wei QY
PLoS One; 2013; 8(9):e71994. PubMed ID: 24023723
[TBL] [Abstract][Full Text] [Related]
3. Association of genetic polymorphisms in DNA repair genes
Alsagaby S; Ahmed AA; Rasheed Z; Althwab SA; Aljohani ASM; Alhumaydhi FA; Alhomaidan HT; Alkhamiss AS; Alkhowailed M; Alaqeel A; Alblihed MA; Alrehaili J; Fernández N; Abdulmonem WA
Nucleosides Nucleotides Nucleic Acids; 2022; 41(5-6):530-554. PubMed ID: 35319340
[TBL] [Abstract][Full Text] [Related]
4. GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population.
Li HY; Ge X; Huang GM; Li KY; Zhao JQ; Yu XM; Bi WS; Wang YL
Asian Pac J Cancer Prev; 2012; 13(7):3465-9. PubMed ID: 22994779
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients.
Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Valdivia-Bautista J; Faus-Dáder MJ; Calleja-Hernández MÁ
Pharmacogenomics J; 2019 Apr; 19(2):164-177. PubMed ID: 29662106
[TBL] [Abstract][Full Text] [Related]
6. Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma.
Puerta-García E; Urbano-Pérez D; Carrasco-Campos MI; Pérez-Ramírez C; Segura-Pérez A; Calleja-Hernández ; Cañadas-Garre M
Surg Oncol; 2020 Dec; 35():388-398. PubMed ID: 33035787
[TBL] [Abstract][Full Text] [Related]
7. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
[TBL] [Abstract][Full Text] [Related]
8. Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer.
Yu WH; Wang YX; Guo JQ; Wang YL; Zheng JS; Zhu KX
Genet Mol Res; 2015 Dec; 14(4):17529-35. PubMed ID: 26782397
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?
Fariña Sarasqueta A; van Lijnschoten G; Lemmens VE; Rutten HJ; van den Brule AJ
Mol Diagn Ther; 2011 Oct; 15(5):277-83. PubMed ID: 21958378
[TBL] [Abstract][Full Text] [Related]
10. Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.
Ji M; Xu B; Jiang JT; Wu J; Li XD; Zhao WQ; Zhang HY; Zhou WJ; Wu CP
Onkologie; 2013; 36(6):335-40. PubMed ID: 23774147
[TBL] [Abstract][Full Text] [Related]
11. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.
Yin M; Yan J; Martinez-Balibrea E; Graziano F; Lenz HJ; Kim HJ; Robert J; Im SA; Wang WS; Etienne-Grimaldi MC; Wei Q
Clin Cancer Res; 2011 Mar; 17(6):1632-40. PubMed ID: 21278243
[TBL] [Abstract][Full Text] [Related]
12. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
[TBL] [Abstract][Full Text] [Related]
13. [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
Liang J; Li QF; Yao RY; Lü HY; Jiang J; Sun YY; Song SA; Jiang T
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):515-9. PubMed ID: 21029695
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
Mo J; Luo M; Cui J; Zhou S
Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
[TBL] [Abstract][Full Text] [Related]
15. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
[TBL] [Abstract][Full Text] [Related]
16. A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
Cordova-Delgado M; Bravo ML; Cumsille E; Hill CN; Muñoz-Medel M; Pinto MP; Retamal IN; Lavanderos MA; Miquel JF; Rodriguez-Fernandez M; Liao Y; Li Z; Corvalán AH; Armisén R; Garrido M; Quiñones LA; Owen GI
BMC Cancer; 2021 Sep; 21(1):1030. PubMed ID: 34525956
[TBL] [Abstract][Full Text] [Related]
17. Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.
Hardi H; Melki R; Boughaleb Z; El Harroudi T; Aissaoui S; Boukhatem N
BMC Cancer; 2018 Mar; 18(1):292. PubMed ID: 29544444
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis.
Shahnam A; Ridha Z; Wiese MD; Kichenadasse G; Sorich MJ
Pharmacogenomics; 2016 Oct; 17(15):1725-1732. PubMed ID: 27636246
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer.
Zhou J; Liu ZY; Li CB; Gao S; Ding LH; Wu XL; Wang ZY
Tumour Biol; 2015 Apr; 36(4):3017-23. PubMed ID: 25542228
[TBL] [Abstract][Full Text] [Related]
20. Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy.
Geng R; Chen Z; Zhao X; Qiu L; Liu X; Liu R; Guo W; He G; Li J; Zhu X
PLoS One; 2014; 9(12):e116027. PubMed ID: 25545243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
